Literature DB >> 9292812

Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis.

D M Eisenstein1, M R O'Gorman, L M Pachman.   

Abstract

OBJECTIVE: To investigate whether changes in peripheral blood lymphocytes correlate with changes in disease activity in juvenile dermatomyositis (JDM).
METHODS: Clinical changes in disease expression measured by a disease activity score were correlated with changes in percentages of peripheral blood lymphocyte subsets.
RESULTS: Changes in the percentage of peripheral blood CD19 positive lymphocytes (B cells) correlated with changes in disease activity (Spearman rank coefficients = 0.47, p = 0.02). There were no significant correlations in disease activity with changes of T cell subsets or the T cell activation markers CD25 or DR.
CONCLUSION: Change in the percentage of peripheral blood B cells correlates with change in disease activity in patients with JDM. This variable may be of use as an indicator of immunologic activity and response to therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292812

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.

Authors:  M Aleksza; A Szegedi; P Antal-Szalmás; B Irinyi; L Gergely; A Ponyi; J Hunyadi; S Sipka; M Zeher; G Szegedi; K Dankó
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

4.  Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis.

Authors:  Dong Xue Wang; Xin Lu; Ning Zu; Bing Lin; Li Ying Wang; Xiao Ming Shu; Li Ma; Guo Chun Wang
Journal:  Clin Rheumatol       Date:  2012-08-30       Impact factor: 2.980

5.  Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis.

Authors:  M R O'Gorman; L Bianchi; D Zaas; V Corrochano; L M Pachman
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

6.  Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

Authors:  K Mizuno; A Yachie; S Nagaoki; H Wada; K Okada; M Kawachi; T Toma; A Konno; K Ohta; Y Kasahara; S Koizumi
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 7.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 8.  The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy.

Authors:  Shabina M Sultan
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

9.  Potential role of autophagy in T‑cell survival in polymyositis and dermatomyositis.

Authors:  Xiaoming Shu; Fang Chen; Qinglin Peng; Xin Lu; Xiaolan Tian; Yan Wang; Guochun Wang
Journal:  Mol Med Rep       Date:  2017-06-06       Impact factor: 2.952

10.  CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α.

Authors:  Christopher J M Piper; Meredyth G Ll Wilkinson; Claire T Deakin; Georg W Otto; Stefanie Dowle; Chantal L Duurland; Stuart Adams; Emiliano Marasco; Elizabeth C Rosser; Anna Radziszewska; Rita Carsetti; Yiannis Ioannou; Philip L Beales; Daniel Kelberman; David A Isenberg; Claudia Mauri; Kiran Nistala; Lucy R Wedderburn
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.